A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
Clara Health

Study of SARS-CoV-2 Patients Testing Nasal Swabs and Collecting Blood Samples for Research

Sponsored by Dr. Deneen Vojta with PATH, Mayo Clinic, and the Bill and Melinda Gates Foundation


This work will serve both the Everett Clinic and broader UnitedHealth Group patient populations as well as advance the public health emergency response to the community spread of SARS-CoV-2 virus, especially as the number of cases and deaths continues to rise in many geographies. A recent study conducted at The Everett Clinic showed that foam nasal swabs were able to detect SARS-CoV-2 virus at comparable levels to nasopharyngeal (NP) swabs.

We now look to build of this work by comparing polyester foam swabs, which are more readily available and mass producible, to foam nasal swabs, in their sensitivity for detecting SARS-CoV-2 virus.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study Type: Observational Estimated Enrollment: 120 participants Actual Study Start Date: March 25, 2020 Estimated Study Completion Date: April 10, 2020

Who is this study for?

Study Population All patients who previously tested positive for SARS-CoV-2 virus at the Everett Clinic within the last month will be contacted and evaluated based on the inclusion/exclusion criteria.

Inclusion Criteria*:

  • Existing patient of the Everett Clinic (i.e., has previously sought care)
  • Tested positive for SARS-CoV-2 virus (confirmed by RT-PCR) prior to time of enrollment

Exclusion Criteria*:

  • Not able to safely travel to the clinic without endangering themselves or risking exposing others to SARS-CoV-2
  • Medical history evidencing any of the following
    • Active nosebleed in the past 24 hours
    • Chemotherapy treatment with low platelet and low white blood cell counts
  • Advanced COVID-19 state that would preclude safe and feasible sample collection

* Additional criteria apply. Please speak with the study team for further information.

What should I expect?

Minimal risk research study:

  • Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus;
  • Quantifying the development and trajectory of the disease through clinic visits and blood values.
Inpatient trial

Have questions or need help?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.